Market open
Cytek Biosciences/$CTKB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Cytek Biosciences
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Ticker
$CTKB
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
645
Website
CTKB Metrics
BasicAdvanced
$867M
Market cap
-
P/E ratio
-$0.08
EPS
1.32
Beta
-
Dividend rate
Price and volume
Market cap
$867M
Beta
1.32
52-week high
$9.87
52-week low
$4.66
Average daily volume
813K
Financial strength
Current ratio
6.214
Quick ratio
5.262
Long term debt to equity
2.333
Total debt to equity
3.766
Interest coverage (TTM)
-20.35%
Management effectiveness
Return on assets (TTM)
-2.74%
Return on equity (TTM)
-2.54%
Valuation
Price to revenue (TTM)
4.406
Price to book
2.27
Price to tangible book (TTM)
2.5
Price to free cash flow (TTM)
31.099
Growth
Revenue change (TTM)
9.88%
Earnings per share change (TTM)
-26.23%
3-year revenue growth (CAGR)
18.91%
3-year earnings per share growth (CAGR)
91.58%
What the Analysts think about CTKB
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cytek Biosciences stock.
CTKB Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CTKB Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CTKB News
AllArticlesVideos
Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewsWire·3 weeks ago
Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program
GlobeNewsWire·3 weeks ago
Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cytek Biosciences stock?
Cytek Biosciences (CTKB) has a market cap of $867M as of December 11, 2024.
What is the P/E ratio for Cytek Biosciences stock?
The price to earnings (P/E) ratio for Cytek Biosciences (CTKB) stock is 0 as of December 11, 2024.
Does Cytek Biosciences stock pay dividends?
No, Cytek Biosciences (CTKB) stock does not pay dividends to its shareholders as of December 11, 2024.
When is the next Cytek Biosciences dividend payment date?
Cytek Biosciences (CTKB) stock does not pay dividends to its shareholders.
What is the beta indicator for Cytek Biosciences?
Cytek Biosciences (CTKB) has a beta rating of 1.32. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.